Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Front Endocrinol (Lausanne). 2021 Nov 19;12:785175. doi: 10.3389/fendo.2021.785175. eCollection 2021.
Thyroid hormones are essential for the full thermogenic response of brown adipose tissue (BAT) and have been implicated in dermal temperature regulation. Nevertheless, persistent cold-intolerance exists among a substantial proportion of hypothyroid patients on adequate levothyroxine (LT4) substitution.
To assess if skin temperature and activation of BAT during treatment with liothyronine (LT3) differs from that of LT4 treatment, fifty-nine female hypothyroid patients with residual symptoms on LT4 or LT4/LT3 combination therapy were randomly assigned in a non-blinded crossover study to receive monotherapy with LT4 or LT3 for 12 weeks each. Change in supraclavicular (SCV) skin temperature overlying BAT, and sternal skin temperature not overlying BAT, during rest and cold stimulation were assessed by infrared thermography (IRT). In addition, abundance of exosomal miR-92a, a biomarker of BAT activation, was estimated as a secondary outcome.
Cold stimulated skin temperatures decreased less with LT3 . LT4 in both SCV (mean 0.009°C/min [95% CI: 0.004, 0.014]; <0.001) and sternal areas (mean 0.014°C/min [95% CI: 0.008, 0.020]; <0.001). No difference in serum exosomal miR-92a abundance was observed between the two treatment groups.
LT3 may reduce dermal heat loss. Thermography data suggested increased BAT activation in hypothyroid patients with cold-intolerance. However, this finding was not corroborated by assessment of the microRNA biomarker of BAT activation.
ClinicalTrials.gov, identifier NCT03627611.
甲状腺激素对于棕色脂肪组织(BAT)的完全产热反应至关重要,并与皮肤温度调节有关。然而,相当一部分甲状腺功能减退症患者在接受足够的左甲状腺素(LT4)替代治疗后仍然存在持续的怕冷现象。
为了评估三碘甲状腺原氨酸(LT3)治疗与 LT4 治疗相比是否会导致皮肤温度和 BAT 激活的变化,59 名女性甲状腺功能减退症患者在接受 LT4 或 LT4/LT3 联合治疗时有残留症状,他们被随机分配到非盲交叉研究中,分别接受 LT4 或 LT3 单药治疗,每种治疗持续 12 周。通过红外热成像(IRT)评估 BAT 上的锁骨上(SCV)皮肤温度和不覆盖 BAT 的胸骨皮肤温度在休息和冷刺激期间的变化。此外,还估计了外泌体 miR-92a 的丰度,作为次要终点。
LT3 治疗时,冷刺激皮肤温度下降较少,SCV(平均 0.009°C/min [95% CI:0.004,0.014];<0.001)和胸骨区域(平均 0.014°C/min [95% CI:0.008,0.020];<0.001)。两种治疗组之间血清外泌体 miR-92a 丰度无差异。
LT3 可能减少皮肤热量损失。热成像数据表明,怕冷的甲状腺功能减退症患者的 BAT 激活增加。然而,这一发现并未得到 BAT 激活的 microRNA 生物标志物评估的证实。
ClinicalTrials.gov,标识符 NCT03627611。